Efruxifermin (EFX): HARMONY, SYMMETRY, FGF21 Analog for MASH
Akero's Efruxifermin (Novo acquired 2025, up to $5.2B): HARMONY 96-wk fibrosis 49% (mITT), SYMMETRY F4 29%/39% by population. Fc-FGF21 deep-dive.
Introduction: Why FGF21 Became the Flagship Class for Fibrosis Regression
In March 2024, Madrigal's Resmetirom (Rezdiffra) became the first FDA-approved MASH drug under accelerated approval, but it exposed a sobering reality: while hepatic steatosis and inflammation improved meaningfully, fibrosis improvement capped at roughly 25% (see MAESTRO-NASH deep-dive). In August 2025, semaglutide (Wegovy) also gained FDA approval for noncirrhotic MASH with moderate-to-advanced fibrosis, sharpening the divide between metabolic/weight-loss agents and dedicated antifibrotics. Post-Resmetirom, the FGF21 (Fibroblast Growth Factor 21) analog class rose to the top of the pipeline watchlist.
The flagship candidate is Efruxifermin (EFX, AKR-001) from Akero Therapeutics. In HARMONY Ph2b, the 24-week primary analysis met its histologic endpoint (fibrosis ≥1-stage improvement without MASH worsening), and 96-week extension data sustained a 49% fibrosis improvement rate in the mITT population (vs 19% placebo, p=0.0030). In the SYMMETRY trial — the first to tackle F4 compensated cirrhosis — Efruxifermin delivered a week-96 cirrhosis reversal rate of 29% (ITT) / 39% (week-96 biopsy set), uncharted territory in MASH. In December 2025, Novo Nordisk completed its acquisition of Akero for up to $5.2B, crowning EFX as the symbol of the MASH tectonic shift.
Within the broader MASH treatment landscape, Efruxifermin stands out as the FGF21 candidate carrying the most advanced late-stage clinical data among unapproved next-generation antifibrotics.
1. Development and Regulatory Snapshot
| Item | Detail |
|---|---|
| INN / Code | Efruxifermin (EFX, AKR-001) |
| Sponsor | Akero Therapeutics (wholly-owned subsidiary of Novo Nordisk since Dec 2025) |
| Modality | Bivalent Fc-FGF21 fusion protein (modified FGF21 linked to human IgG1 Fc, extending half-life) |
| Route | Subcutaneous, once weekly |
| Pivotal trials | HARMONY (NCT04767529), SYMMETRY (NCT05039450), SYNCHRONY Ph3 program (3 studies) |
| FDA designation | Breakthrough Therapy Designation (December 8, 2022, for MASH) |
| Current status | SYNCHRONY Histology / Real-World / Outcomes trials ongoing; readouts expected 2026-2027 |
| Acquisition | Novo Nordisk completed acquisition on December 9, 2025 for up to $5.2B ($54/share + $6/share CVR contingent on F4 MASH approval) |
For researchers tracking fibrosis & inflammation R&D
FDA approval alerts, trial readouts, preclinical model selection, and assay optimization — curated signal for bench-to-pipeline readers. 2 emails/month max.
2. The Unmet Need: Why FGF21 Is Theoretically Superior
MASH is not merely "fatty liver from obesity" but a three-layer disease: (1) metabolic dysfunction (insulin resistance, lipid accumulation), (2) chronic inflammation, (3) fibrosis. Resmetirom accelerates hepatic lipid metabolism via THR-β but struggles to reverse established F3/F4 fibrosis.
FGF21 is an endocrine hormone produced in liver and adipose tissue, signaling via the FGFR1c/2c/3c receptor complex with the coreceptor β-Klotho (KLB). Its downstream effects are multi-layered:
- Adipose tissue: promotes adiponectin secretion → improves insulin sensitivity, suppresses hepatic lipid influx
- Liver: accelerates fatty acid β-oxidation, suppresses de novo lipogenesis, relieves ER stress
- Hepatic stellate cells (HSCs): suppresses activation, induces deactivation → direct antifibrotic action
- Inflammation: skews Kupffer cells toward M2, suppresses TGF-β1 and IL-6
Efruxifermin's Fc fusion extends plasma half-life to approximately 3-3.5 days, enabling once-weekly dosing and sustained FGF21 pathway activation.
3. Mechanism: The Engineering Behind Fc-FGF21 Fusion
Native FGF21 has an extremely short plasma half-life (<1 hour), limiting clinical use. Efruxifermin overcomes this via:
- Bivalent FGF21 × IgG1 Fc: two FGF21 moieties simultaneously engage two FGFR1c-KLB complexes, amplifying signal intensity. The Fc portion enables FcRn-mediated recycling for extended half-life.
- Adiponectin induction: Ph1/Ph2 trials showed 2-3× elevation within 2 weeks, serving as a pharmacodynamic biomarker.
- HSC deactivation: suppresses α-SMA and type I collagen expression linked to hepatic stellate cell activation in fibrosis; Sirius Red quantification confirms reduction in preclinical models.
Crucially, whereas GLP-1 agents drive fibrosis improvement indirectly via weight loss, FGF21 analogs do not rely on weight reduction as their primary mechanism the way GLP-1/GCG agents do, targeting fibrosis largely independent of weight. This profile carries particular significance for lean MASH, which is prevalent in Japanese populations.
4. Clinical Evidence: HARMONY / SYMMETRY / SYNCHRONY
4.1 HARMONY Ph2b (F2-F3 Pre-Cirrhotic MASH)
| Item | Detail |
|---|---|
| Trial | HARMONY (NCT04767529) |
| Design | Multicenter, randomized, double-blind, placebo-controlled |
| Population | F2-F3 MASH (n=128) |
| Dosing | EFX 28 mg or 50 mg SC weekly vs placebo |
| 24-wk primary endpoint | Fibrosis improvement ≥1 stage without worsening of MASH |
| Publication | Harrison SA et al., Lancet Gastroenterol Hepatol 2023;8(12):1080-1093 (PMID 37802088) |
| 96-wk extension | The Lancet 2025 (Akero IR, August 2025) |
Key results:
- 24-wk primary endpoint (liver-biopsy analysis set, LBAS): fibrosis ≥1-stage improvement without MASH worsening reached 39% (15/38, p=0.025) for EFX 28 mg and 41% (14/34, p=0.036) for 50 mg vs 20% (8/41) placebo → both doses met the primary endpoint
- 96-wk extension (mITT): 50 mg arm 49% fibrosis improvement vs placebo 19% (p=0.0030); in the week-96 biopsy-available set the figures are 75% vs 24% (p<0.0001) — the same outcome differs by analysis population → clear separation with sustained dosing
- Secondary endpoints: MASH resolution, LDL reduction, HbA1c improvement, 2-3× adiponectin increase
- Safety: diarrhea, nausea, injection-site reactions predominant, generally mild to moderate; no head-to-head comparison with GLP-1 agents is available; serious AEs uncommon
Important clarification: The "HARMONY 96-wk fibrosis improvement 75%" figure is not an error — it refers to the week-96 biopsy-available population (50 mg, 21/28). The mITT figure is 49% vs 19%; the two reflect different analysis populations and should always be cited with the population named.
4.2 SYMMETRY Ph2b (F4 Compensated Cirrhosis)
F4 cirrhosis has long been considered a point of no return; no prior drug had demonstrated cirrhosis reversal. Akero deliberately targeted this uncharted frontier.
| Item | Detail |
|---|---|
| Trial | SYMMETRY (NCT05039450) |
| Population | F4 compensated MASH cirrhosis; randomized n=181 (week-96 biopsy set n=134) |
| Dosing | EFX 28 mg / 50 mg weekly vs placebo, 96 weeks |
| Publication | Noureddin M et al., N Engl J Med 2025;392(24):2413-2424 (PMID 40341827; DOI 10.1056/NEJMoa2502242); EASL 2025 oral presentation |
Key results:
- 36-wk primary endpoint: fibrosis improvement did not reach significance (F4 responds slowly)
- 96-wk cirrhosis reversal (50 mg): 29% vs placebo 11% (ITT, n=181, p<0.05) and 39% vs placebo 15% (week-96 biopsy set, n=134, p<0.01) — figures differ by analysis population → meaningful regression from cirrhosis to F3 or lower
- Improvements in MELD score, platelet count, and NITs (ELF, VCTE) (exploratory)
Although the 36-week primary endpoint was not met, SYMMETRY was the first randomized trial to show a week-96 fibrosis-regression signal in MASH cirrhosis, strengthening the clinical standing of the FGF21 class.
4.3 SYNCHRONY Phase 3 Program (Three Trials)
Based on HARMONY/SYMMETRY, Akero launched a comprehensive F1-F4 Ph3 program:
| Trial | Population | NCT | Readout |
|---|---|---|---|
| SYNCHRONY Histology | F2-F3 pre-cirrhotic MASH (biopsy) | NCT06215716 | 2026-2027 |
| SYNCHRONY Real-World | F1-F3 MASH/MASLD (non-invasive dx) | NCT06161571 | Enrollment complete, H1 2026 |
| SYNCHRONY Outcomes | F4 compensated cirrhosis | NCT06528314 | First dose Sep 2024, long-term |
5. Competitive Positioning
| Drug | Target | Key Data | Status |
|---|---|---|---|
| Efruxifermin | Fc-FGF21 | HARMONY 96-wk 49% (mITT); SYMMETRY F4 29% ITT / 39% biopsy set | Ph3 ongoing, 2026-2027 readouts |
| Resmetirom | THR-β | MAESTRO-NASH 24-26% fibrosis improvement | FDA accelerated approval Mar 2024 |
| Pegozafermin | PEG-FGF21 | ENLIVEN Ph2b 26% (30 mg weekly) | Ph3 ENLIGHTEN, 2027 readout |
| Efimosfermin | FGF21 | Ph2b fibrosis improvement | GSK acquired from Boston Pharma ($1.2B upfront, up to $2.0B total, May 2025), Ph3-ready |
| Survodutide | GLP-1/GCG | Ph2 MASH 62%; F2-F3 fibrosis 64.5% | LIVERAGE Ph3 |
| Lanifibranor | Pan-PPAR | NATIVE Ph2b 49% | NATiV3 Ph3, H2 2026 |
Efruxifermin's positioning: the most clinically advanced FGF21 candidate, and the only one with meaningful F4 cirrhosis data. Novo Nordisk's mega-deal underscores the industry's high expectations for the FGF21 class. A Resmetirom (THR-β) + EFX (FGF21) combination is one of the leading hypotheses for future MASH treatment algorithms.
6. Preclinical Evidence and Recommended Models
Akero has published limited preclinical data, but primary sources include:
| Study | Key Findings | Reference |
|---|---|---|
| T2D patient PD study (AKR-001) | Single/repeat dosing: adiponectin increase, triglyceride/LDL reduction, improved insulin sensitivity | Kaufman A et al., Cell Rep Med 2020 (PMID 33205064) |
| Rat pharmacology (Efruxifermin) | Reduced body-weight gain in rats without increasing sympathetic tone or urine volume — atypical pharmacological profile for an Fc-FGF21 | Tillman EJ et al., Br J Pharmacol 2022;179(7):1384-1394 (PMID 34773249) |
Recommended Preclinical Workflow
As discussed in MASH model selection, model choice determines outcome:
- GAN DIO-MASH mouse: long-term dietary model. Reproduces fibrosis progression alongside metabolic disease — standard for antifibrotic + metabolic agents
- STAM model: rapid NASH → HCC progression; useful for tumorigenesis endpoints
- db/db + dietary: pronounced insulin resistance, ideal for FGF21 pathway responsiveness
- CDA-HFD model: accelerated fibrosis; supports early antifibrotic PoC
Recommended endpoints:
- Fibrosis: hydroxyproline, Sirius Red, α-SMA staining
- Metabolic: plasma adiponectin, fasting insulin, liver triglyceride
- Histology: NAS, CRN fibrosis stage, ballooning score
- Molecular: FGF21 downstream (phospho-ERK), SREBP-1c, collagen I/III
7. Key Forward-Looking Questions
- SYNCHRONY Ph3 primary readouts (2026-2027): Real-World (non-invasive diagnostic endpoint) expected H1 2026; Histology Ph3 forms the basis of registration
- Novo Nordisk's strategic intent: The GLP-1 giant's move for FGF21 is consequential. A semaglutide × EFX combination is a notable development hypothesis integrating metabolic and antifibrotic mechanisms
- CVR on F4 approval: The $6/share CVR in the acquisition is contingent on F4 approval. SYMMETRY follow-up data could trigger ~$500M additional payout
- Differentiation vs Pegozafermin / Efimosfermin: Indirect comparisons among the three FGF21 analogs will likely dominate AASLD 2026-2027
- Japan launch timeline: Akero did not pursue Japanese development directly; Novo Nordisk's Wegovy infrastructure offers a rapid path. Lean MASH inclusion in Japanese Ph3 is plausible
References
- Harrison SA, Frias JP, Neff G, et al. Safety and efficacy of once-weekly efruxifermin versus placebo in non-alcoholic steatohepatitis (HARMONY): a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial. Lancet Gastroenterol Hepatol. 2023;8(12):1080-1093. PMID: 37802088
- Noureddin M, et al. Efruxifermin in Compensated Liver Cirrhosis Caused by Metabolic Dysfunction-Associated Steatohepatitis. N Engl J Med. 2025;392(24):2413-2424. PMID: 40341827. DOI: 10.1056/NEJMoa2502242
- Kaufman A, Abuqayyas L, Denney WS, Tillman EJ, Rolph T. AKR-001, an Fc-FGF21 Analog, Showed Sustained Pharmacodynamic Effects on Insulin Sensitivity and Lipid Metabolism in Type 2 Diabetes Patients. Cell Rep Med. 2020;1(4):100057. PMID: 33205064
- Tillman EJ, Brown SL, Rolph T. Efruxifermin, an Fc-FGF21 analogue, possesses an atypical pharmacological profile in rats. Br J Pharmacol. 2022;179(7):1384-1394. PMID: 34773249
- Akero Therapeutics. HARMONY 96-Week Data Announcement. August 2025. The Lancet 2025.
- Novo Nordisk. Novo Nordisk has completed its acquisition of Akero Therapeutics. Press release, December 9, 2025.
- HARMONY Ph2b: NCT04767529
- SYMMETRY Ph2b (F4): NCT05039450
- SYNCHRONY Histology Ph3: NCT06215716
- SYNCHRONY Real-World Ph3: NCT06161571
- SYNCHRONY Outcomes Ph3: NCT06528314
- Akero Therapeutics. FDA Grants Breakthrough Therapy Designation to Efruxifermin for NASH. Press release, December 8, 2022.
Related Articles
- MASH Treatment Landscape: Comprehensive Analysis — full evidence review across approved drugs and pipeline
- Survodutide (GLP-1/GCG dual agonist): MASH fibrosis 64.5% — the combination-therapy partner on the incretin side
- Resmetirom approval: MAESTRO-NASH deep dive — THR-β × FGF21 combination foundation
- MASH combination therapy 2026: acquisition strategy — Madrigal / GSK / Sagimet portfolio battle
- Liver antifibrotic pipeline 2026 — FGF21 / GLP-1 multi-agonist business view
- MASH animal model selection — GAN DIO / STAM / CDA-HFD comparison
- Semaglutide for MASH: the reality check — limitations of GLP-1 monotherapy on fibrosis